'From Medication to Maintenance: A Nutritionist’s Guide to Sustaining Weight Loss Beyond GLP-1 Therapy'

Is there any data on the impact on the microbiome? If people are eating less, and many people are not considering what they are putting into their body, there are big risks to overall health due to nutrient deficiencies, there’s also then muscle wastage and fatigue, (which you have just mentioned) mental health complications – why aren’t more people looking at proper solutions -fixing our farming and quality of foods. it feels like everything is about profit instead of root cause solutions and I find this really challenging.
This is an excellent and very important question. Yes, there is growing evidence that both obesity itself and modern dietary patterns significantly alter the gut microbiome. Diets high in ultra-processed foods and low in fibre reduce microbial diversity and reduce production of beneficial short-chain fatty acids such as butyrate. One of the concerns with GLP-1 therapies is that whilst people often eat less, they do not necessarily eat better. If dietary quality declines alongside calorie intake, there is potential risk for micronutrient deficiencies, reduced fibre intake, loss of microbial diversity, muscle wasting, fatigue, and potentially poorer long-term metabolic resilience.

We also know that ultra-processed foods are often rich in advanced glycation end products and highly refined carbohydrates, both of which may contribute to inflammatory signalling and metabolic dysfunction.

I completely agree that obesity medicine cannot simply be reduced to pharmaceuticals. Food quality, farming systems, soil quality, food processing, sleep, stress, movement, environmental exposures, and socioeconomic factors all matter enormously. However, I also think we need to acknowledge that many patients are already metabolically unwell by the time they present clinically. For some individuals, pharmacotherapy can create a physiological ‘window of opportunity’ where appetite and food noise are reduced enough for healthier behavioural patterns to become achievable. So ideally, the future model is not medication versus lifestyle — it’s integrated metabolic care addressing both biology and root causes simultaneously.

I’m struggling to help an autistic gentleman in independent living. weight loss on mounjaro is slow , any strategy reccomendations? to help with weight loss
This is a very important clinical scenario because neurodivergent individuals often face unique challenges around food, routine, sensory preferences, emotional regulation, sleep, and activity patterns. Firstly, I would avoid comparing his rate of weight loss to population averages. Some patients respond very rapidly, others much more gradually, and that variability is completely normal.

In autistic individuals specifically, several areas can be helpful:

• maintaining highly structured routines,
• predictable meal timing,
• reducing sensory-trigger foods,
• improving sleep regularity,
• minimising ultra-processed foods where feasible,
• and focusing on safe, acceptable protein and fibre sources.

Food texture and sensory tolerance often matter more than clinicians initially realise. Exercise strategies may also need adaptation. Some individuals respond better to repetitive, structured movement rather than traditional gym-based approaches. Importantly, stress and anxiety can significantly affect eating behaviour and cortisol signalling, so psychological safety and routine consistency become very important. And finally, if weight loss is slow but metabolic health markers are improving — energy, HbA1c, waist circumference, mobility, inflammatory markers — that is still clinically meaningful progress.

You mentioned that this is a natural approach. But where do the compounds within the Go Lean products come from?
The ingredients are derived from botanical and nutritional sources. For example:

• glucomannan comes from konjac root,
• curcumin from turmeric,
• resveratrol from plant polyphenols such as grapes,
• berberine from plants including Berberis species,
• green tea catechins from Camellia sinensis,
• cinnamon extracts from cinnamon bark,
• and mulberry extracts from white mulberry leaf.

These compounds are then standardised and formulated into concentrated nutraceutical preparations.

Importantly though, whilst the ingredients are naturally derived, they still exert biological activity and should be viewed as functional metabolic support rather than simply ‘wellness products.’ And importantly, they are not intended to replicate the potency of pharmaceutical GLP-1 agonists. The goal is more supportive metabolic modulation alongside nutrition and lifestyle strategies.

Are there some people who experience food addiction, who need to be on micro doses of GLP1s (or remove certain trigger foods from their diet such as added sugar and refined carbohydrates)
Yes — I think this is likely true for some individuals. There is increasing evidence that highly processed hyperpalatable foods can activate reward pathways in ways that resemble addictive neurobiology in susceptible individuals. Not everyone experiences food this way, but some patients clearly describe compulsive eating behaviours, loss of control, persistent cravings, and strong reward-driven responses to refined carbohydrates and added sugars. For some people, complete abstinence from specific trigger foods may actually be easier than moderation. And for others, low-dose long-term GLP-1 therapy may ultimately become similar to chronic treatment models we already use in hypertension or depression.

I suspect obesity medicine will increasingly move toward personalised long-term management rather than assuming everyone can discontinue treatment permanently. The key is identifying which patients are experiencing predominantly hedonic eating, emotional eating, reward-driven eating, or true physiological hunger.

What if the food noise isn’t there but still gaining weight?
That’s a really important distinction because appetite is only one component of weight regulation. Weight gain can still occur in the absence of food noise due to:

• low energy expenditure,
• metabolic adaptation,
• loss of lean mass,
• endocrine issues,
• poor sleep,
• high cortisol,
• medications,
• insulin resistance,
• menopause-related hormonal changes,
• or reduced movement during the day.

Some patients also unconsciously consume highly energy-dense foods without strong hunger perception. This is why body composition, protein intake, movement patterns, sleep quality, stress physiology, and metabolic health all matter alongside appetite itself. And importantly, some individuals may have relatively low hunger but still have impaired metabolic flexibility or low resting metabolic rate.

I am a GP and Health Coach and want to know what the evidence is for the Gp Lean Plus as I have several private clients trying to come off GLP-1 and would recommend this but would like to be able to refer to results? My clients are eating three meals, protein and doing exercise and mindset shift work with me but still struggling. Does titrating very slowly off GLp-1 help with coming off
At present, the evidence base is strongest for the individual ingredients rather than the final combined formulation itself.

Many ingredients within the product — such as glucomannan, green tea catechins, berberine, curcumin, resveratrol, and polyphenols — have supportive evidence from systematic reviews and meta-analyses relating to satiety, glycaemic control, inflammation, or body composition. However, it’s important to remain scientifically balanced and acknowledge that nutraceuticals generally produce modest effects compared with pharmaceutical GLP-1 agonists. In practice, I would position the product as part of a broader maintenance framework:

• structured meals,
• adequate protein,
• resistance training,
• sleep optimisation,
• behavioural support,
• and gradual appetite transition.

And yes — clinically, very slow titration off GLP-1 therapies does appear helpful for many patients.

A gradual reduction may allow appetite signalling, behavioural adaptation, meal structure, and metabolic regulation to stabilise more progressively rather than producing an abrupt rebound.

How long would you expect to be working with a patient for, after they come off the GLP-1?
Realistically, I think patients often require structured support for at least 6–12 months after cessation, and in some cases longer. The highest risk period for weight regain is usually within the first year because biological compensation is strongest during this phase. What we’re really trying to do is transition patients from pharmacological appetite control toward sustainable behavioural and metabolic resilience. That takes time. In many ways, obesity maintenance should probably be viewed similarly to rehabilitation — gradual, structured, adaptive, and highly individualised.”

Down syndrome people have generally weight issues. Could they be on this medication long term?
“This is an area where we still need more specific long-term research.

Individuals with Down syndrome often experience increased obesity risk due to a combination of:

• lower resting metabolic rate,
• hypotonia,
• endocrine abnormalities,
• reduced activity,
• sleep apnoea,
• and behavioural or environmental factors.

Some individuals may potentially benefit from long-term pharmacotherapy, particularly where obesity is significantly affecting metabolic or cardiovascular health. However, careful monitoring would be extremely important because nutritional adequacy, muscle preservation, gastrointestinal symptoms, and overall functional status may be especially relevant in this population. As always, decisions should remain highly individualised and ideally involve multidisciplinary support including medical, nutritional, behavioural, and caregiver input.”

Recipe Book: www.ihcansummit.co.uk/downloads/2026/webinars/everanutrition-recipebook.pdf